Lu-AAZTA-NI-PSMA-093 enhances tumor uptake and retention by combining a hypoxia-sensitive nitroimidazole (NI) moiety with a targeting moiety to PSMA. Lu-AAZTA-NI-PSMA-093 can be used in prostate cancer[1].
Molecular Weight:
1626.37
Formula:
C63H82LuN14O26
Target:
Radionuclide-Drug Conjugates (RDCs)
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted